Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study

Journal of Clinical Oncology

Volumn 28, Issue 11, 2010, Pages 3191-3198

  Tebbutt, Niall C ^b   Wilson, Kate ^a,d   Gebski, Val J ^a,d   Cummins, Michelle M ^a   Zannino, Diana ^a   Van Hazel, Guy A ^a,e   Robinson, Bridget ^a,f   Broad, Adam ^a,g   Ganju, Vinod ^a   Ackland, Stephen P ^a   Forgeson, Garry ^a,i   Cunningham, David ^a,ak   Saunders, Mark P ^a,o   Stockler, Martin R ^a   Chua, Yujo ^a   Zalcberg, John R ^a   Simes, R John ^a,d   Price, Timothy J ^a,c   Coates, Alan ^aq   O'Connell, Diane ^aq   Brown, Chris ^aq   Hague, Wendy ^aq   France, Alyson ^aq   Hicks, Sian ^aq   James, Rebecca ^aq   Masson, Ruby ^aq   O'Connell, Rachel ^aq   Pike, Rhana ^aq   Shoulder, Julia ^aq   Stevens, Lindsay ^aq   Tunney, Victoria ^aq   Vachan, Burcu ^aq   Wong, Nicole ^aq   Ackland, Steve ^h   Moylan, Eugene ^j   Strickland, Andrew ^k   Abdi, Ehtesham ^l   Ransom, David ^m   Lowenthal, Ray ⁿ   Marx, Gavin ^p   Nayagam, Sid Selva ^q   Shannon, Jenny ^r   Goldstein, David ^s   Karapetis, Chris ^t   Blum, Rob ^u   Eek, Richard ^v   Ward, Robyn ^w   Pavlakis, Nick ^x   Wilcken, Nicholas ^y   Burns, Ivon ^z   Wyld, David ^aa   Underhill, Craig ^ab   Claringbold, Philip ^ac   Liauw, Winston ^ad   Clingan, Phil ^ae   Jefford, Michael ^af   Horvath, Lisa ^ag   McKendrick, Joe ^ah   Chong, Geoff ^ai   Boyce, Adam ^aj   Cassidy, Jim ^al   Kirsten, Fred ^am   Clarke, Stephen ^an   Guo, Yuan ^b   Innes Rowe, Judy ^e,ao   Smith, Anne ^f   Williams, Jerneen ^c   Tournier, Elesha ^g   Maliepaard, Sharon ^a   Vitullo, Erica ^h   Humm, Gillian ⁱ   Nguyen, Vu ^j   Midolo, Peter ^k   Chorlton, Charmayne ^l   McDonald, Lily ^m,ap   Oliver, Lesley ⁿ   Sjursen, Ann Marie ^o   Inglis, Clare ^p   Marafioti, Toni ^q   McCourt, Junie ^r   Howard, Julie ^s   Richards, Alison ^t   Provis, Andrea ^ao   Rundle, Amanda ^u   Whatman, Anne ^v   Emmett, Libby ^z   Raymond, Bronwyn ^x   Byrne, Sonia ^y   Withers, Emma ^z   Campbell, Jenny ^aa   Hodgkins, Christopher ^ab   Szwajcer, Michael ^ad   Parker, Sue ^ae   Welby, Sarah ^af   Page, Fiona ^ah   Corker, Mary ^ac   Wykes, Richard ^ag   Goss, Carmel ^ai   Whitney, Suzanne ^aj   Oates, Jacqui ^ak   Soulis, Eileen ^al   Hoque, Mafizul ^am   Gebbie, Chantal ^an   more..

^a FRANKSTON HOSPITAL   (Australia)

^b AUSTIN HEALTH   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^f CHRISTCHURCH HOSPITAL   (New Zealand)

^g GEELONG HOSPITAL   (Australia)

^h CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

ⁱ NORTHERN HOSPITAL   (Australia)

^j LIVERPOOL HOSPITAL   (Australia)

^k MONASH MEDICAL CENTRE   (Australia)

^l The Tweed Hospital   (Australia)

^m ST JOHN OF GOD HOSPITAL   (Australia)

ⁿ ROYAL HOBART HOSPITAL   (Australia)

^o CHRISTIE HOSPITAL   (United Kingdom)

^p Clinical Trials Unit   (Australia)

^q ROYAL ADELAIDE HOSPITAL   (Australia)

^r Nepean Cancer Care Centre   (Australia)

^s PRINCE OF WALES HOSPITAL   (Australia)

^t FLINDERS MEDICAL CENTRE   (Australia)

^u Bendigo Hospital   (Australia)

^v CAMPBELLTOWN HOSPITAL   (Australia)

^w ST VINCENT S HOSPITAL   (Australia)

^x ROYAL NORTH SHORE HOSPITAL   (Australia)

^y WESTMEAD HOSPITAL   (Australia)

^z ST VINCENT S HOSPITAL   (Australia)

^aa ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^ab Border Medical Oncology Australia   (Australia)

^ac FREMANTLE HOSPITAL   (Australia)

^ad ST GEORGE HOSPITAL   (Australia)

^ae Southern Medical Day Care Centre   (Australia)

^af PETER MACCALLUM CANCER CENTRE   (Australia)

^ag ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^ah BOX HILL HOSPITAL   (Australia)

^ai Ballarat Hospital   (Australia)

^aj Lismore Hospital ^*  (Australia)

^ak Department of Histopathology   (Australia)

^al BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^am BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^an Department of Microbiology and Infectious Diseases   (Australia)

^ao Mount Hospital   (Australia)

^ap ROYAL PERTH HOSPITAL   (Australia)

^aq NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; MITOMYCIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUSTRALIA; BLEEDING; COLORECTAL CANCER; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; INFECTION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NEW ZEALAND; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; UNITED KINGDOM; VEIN EMBOLISM; VEIN THROMBOSIS; VOMITING; AUSTRALIA AND NEW ZEALAND; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HYPOTENSION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALASIA; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; FEMALE; FLUOROURACIL; HUMANS; HYPOTENSION; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 77955497309     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.7723     Document Type: Article

References (21)

1. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
2. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
3. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
4. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347-353, 2001 (Pubitemid 32422861)
5. Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370:135-142, 2007 (Pubitemid 47042893)
6. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997 (Pubitemid 27441066)
7. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
8. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
9. Ross P, Norman A, Cunningham D, et al: A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8:995-1001, 1997 (Pubitemid 27475731)
10. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
11. Wagner AD, Arnold D, Grothey AA, et al: Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 3:CD005392, 2009
12. Johnson KR, Ringland C, Stokes BJ, et al: Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis. Lancet Oncol 7:741-746, 2006 (Pubitemid 44283658)
13. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
14. Haller DG, Cassidy J, Clarke SJ, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26:2118-2123, 2008
15. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
16. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
17. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678, 2008
18. Lambrechts D, Delmar P, Buysschaert I, et al: VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer. Eur J Cancer 7:10, 2009 (suppl)
19. Australian Institute of Health and Welfare: Chronic Diseases and Associated Risk Factors in Australia, 2001. Canberra, Australia, Australian Institute of Health and Welfare, 2002
20. Scappaticci FA, Skillings JR, Holden SN, et al: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239, 2007 (Pubitemid 47299901)
21. Kabbinavar FF, Hurwitz HI, Yi J, et al: Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: Pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27:199-205, 2009